Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Emblem Corp. Appoints Nick Dean as Chief Executive Officer


Posted on: 30 Oct 17

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

TORONTO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Emblem Corp. (TSX-V:EMC) (EMC.WT) (“Emblem” or the “Company”), one of Canada’s leading federally-licensed cannabis producers, is pleased to announce the appointment of Nick Dean as the Company’s new Chief Executive Officer effective no later than January 15, 2018, subject to TSX Venture Exchange approval. Mr. Dean succeeds Gordon H. Fox, who has been with the Company since its inception.

Emblem’s Board of Directors is confident this change in leadership will build on the Company’s current success and enhance its position as a leader in the Canadian cannabis market.

“Gordon has guided Emblem through a period of incredible growth with his business acumen and we thank him immensely for his dedication and many contributions as CEO for the past two years,” says Harvey Shapiro, Chair of Emblem's Board of Directors. “We’re delighted to have Nick join our team. We believe his exceptional leadership and consumer marketing experience will build on the foundation Gordon has established and propel us forward in our quest to bring only the highest quality cannabis products to market.”

Mr. Fox joined Emblem in 2013 and assumed the role of CEO in 2015. He has led the Company through several major milestones, including its go public transaction and listing on the TSX Venture Exchange in December 2016. Mr. Fox also oversaw Emblem’s approval by Health Canada to become a licensed medical cannabis producer in Canada and the Company’s significant patient acquisition and overall growth. Mr. Fox will maintain his position on the Emblem Board of Directors and continue to offer his valued expertise and insights at that leadership level.

“My time as CEO of Emblem was both challenging and rewarding, and I am very grateful to have had the opportunity to lead Emblem’s incredibly hard-working team and to contribute to the Company’s many accomplishments,” says Mr. Fox. “Nick is an ideal candidate to step in and lead the company forward in its next chapter in our ever-changing industry. I welcome him to the Emblem family.”

Nick Dean brings more than 12 years of consumer marketing and leadership experience to Emblem’s dedicated team, including extensive work with highly respected pharmaceutical and healthcare brands. Most recently he worked with KBS Canada, a fully integrated creative agency with offices in Toronto and Montreal, where he led the company through two mergers and a number of substantial client wins, resulting in significant bottom and top-line growth. Mr. Dean earned his MBA from the Richard Ivey School of Business and holds his Bachelor of Commerce Degree from McMaster University. He is a proud husband and father of three sons.

“I am excited to join this emerging industry and to bring my experience in creating brands to Emblem,” says Nick Dean, incoming CEO of Emblem. “I am inspired by the vision Gordon and his management team have for the cannabis industry and thank Gordon for the foundation he has put in place. I believe our future is very bright.”

Mr. Dean joins Emblem at a time when cannabis legalization is on the political horizon and the number of medical marijuana patients keeps growing as the medical community embraces the benefits of cannabis to treat a range of medical conditions.

 In connection with Mr. Dean's appointment as CEO, the Company has approved the grant of an aggregate of 500,000 incentive stock options of the Company (the “Options”) to Mr. Dean. Each Option entitles Mr. Dean to purchase one common share in the capital of the Company at a price of $1.69 per share for a period of five years from the date of grant. The Options will vest in three equal tranches with the first tranche to vest on January 15, 2019, the second tranche to vest on January 15, 2020 and the remainder to vest on January 15, 2021. The grant of the Options is subject to the terms of the Stock Option Plan and the approval of the TSX Venture Exchange.

About Emblem

Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR") through its wholly-owned subsidiary Emblem Cannabis Corporation to cultivate and sell medical cannabis. Emblem carries out its principal activities producing cannabis from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

Forward-looking statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (together, "forward-looking statements"). All statements and information contained herein that is not clearly historical in nature may constitute forward-looking statement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company's annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information contact:

Ali Mahdavi
Vice President, Capital Markets and Investor Relations
Emblem Corp.
(416) 962-3300
alimahdavi@emblemcorp.com

GlobeNewswire
globenewswire.com

Last updated on: 30/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.